1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells

Journal of Immunology

Volumn 178, Issue 1, 2007, Pages 145-153

  Penna, Giuseppe ^a   Amuchastegui, Susana ^a   Giarratana, Nadia ^a   Daniel, Kenn C ^a   Vulcano, Marisa ^b   Sozzani, Silvano ^b   Adorini, Luciano ^a  

^a BioXell SpA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CALCITRIOL; CHEMOKINE; CHEMOKINE CCL22; CHEMOKINE RECEPTOR CCR4; INTERLEUKIN 12; INTERLEUKIN 12P75; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL MATURATION; CELL NUCLEUS; CONTROLLED STUDY; CYP24 GENE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; GENE; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; TH1 CELL;

EID: 33845949937     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.1.145     Document Type: Article

References (65)

1. Deluca, H. F., and M. T. Cantorna. 2001. Vitamin D: its role and uses in immunology. FASEB J. 15: 2579-2585.
2. 3 analogs as immunomodulatory agents. Trends Mol. Med. 8: 174-179.
3. Adorini, L. 2002. 1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr. Opin. Investig. Drugs 3: 1458-1463.
4. 3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J. Biol. Chem. 278: 49378-49385.
5. 3. Crit. Rev. Eukaryot. Gene Expr. 8: 19-42.
6. 3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164: 2405-2411.
7. 3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. 164: 4443-4451.
8. Griffin, M. D., W. H. Lutz, V. A. Phan, L. A. Bachman, D. J. McKean, and R. Kumar. 2000. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem. Biophys. Res. Commun. 270: 701-708.
9. van Halteren, A. G., E. van Etten, E. C. de Jong, R. Bouillon, B. O. Roep, and C. Mathieu. 2002. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D3. Diabetes 51: 2119-2125.
10. 3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J. Immunol. 174: 270-276.
11. 3. Blood 106: 3490-3497.
12. Adorini, L., N. Giarratana, and G. Penna. 2004. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin. Immunol. 16: 127-134.
13. Shortman, K., and Y. J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2: 151-161.
14. Colonna, M., G. Trinchieri, and Y. J. Liu. 2004. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5: 1219-1226.
15. Asselin-Paturel, C., and G. Trinchieri. 2005. Production of type 1 interferons: plasmacytoid dendritic cells and beyond. J. Exp. Med. 202: 461-465.
16. Liu, Y. J. 2005. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol 23: 275-306.
17. Penna, G., M. Vulcano, A. Roncari, F. Facchetti, S. Sozzani, and L. Adorini. 2002. Differential chemokine production by myeloid and plasmacytoid dendritic cells. J. Immunol. 169: 6673-6676.
18. Penna, G., S. Sozzani, and L. Adorini. 2001. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J. Immunol. 167: 1862-1866.
19. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21: 685-711.
20. Dzionek, A., A. Fuchs, P. Schmidt, S. Cremer, M. Zysk, S. Miltenyi, D. W. Buck, and J. Schmitz. 2000. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165: 6037-6046.
21. Rogge, L., D. D'Ambrosio, M. Biffi, G. Penna, L. J. Minetti, D. H. Presky, L. Adorini, and F. Sinigaglia. 1998. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J. Immunol. 161: 6567-6574.
22. s cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol. 3: 237-243.
23. Li, Q., and I. M. Verma. 2002. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2: 725-734.
24. Hackstein, H., and A. W. Thomson. 2004. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 4: 24-34.
25. Adorini, L., G. Penna, N. Giarratana, A. Roncari, S. Amuchastegui, K. C. Daniel, and M. Uskokovic. 2004. Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J. Steroid Biochem. Mol. Biol. 89-90: 437-441.
26. Giarratana, N., G. Penna, S. Amuchastegui, R. Mariani, K. C. Daniel, and L. Adorini. 2004. A vitamin D analog downregulates proinfiammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J. Immunol. 173: 2280-2287.
27. 3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 146: 1956-1964.
28. 3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167: 1945-1953.
29. 3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98: 6800-6805.
30. 3 analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes 51: 1367-1374.
31. Andrew, D. P., M. S. Chang, J. McNinch, S. T. Wathen, M. Rihanek, J. Tseng, J. P. Spellberg, and C. G. Bias III. 1998. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J. Immunol. 161: 5027-5038.
32. Imai, T., M. Nagira, S. Takagi, M. Kakizaki, M. Nishimura, J. Wang, P. W. Gray, K. Matsushima, and O. Yoshie. 1999. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int. Immunol. 11: 81-88.
33. + regulatory T cells. J. Exp. Med. 194: 847-853.
34. Vulcano, M., C. Albanesi, A. Stoppacciaro, R. Bagnati, G. D'Amico, S. Struyf, P. Transidico, R. Bonecchi, A. Del Prete, P. Allavena, et al. 2001. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur. J. Immunol. 31: 812-822.
35. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
36. + T-cells in B-cell non-Hodgkin lymphoma. Blood 107: 3639-3646.
37. Gilliet, M., and Y. J. Liu. 2002. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195: 695-704.
38. + regulatory T cells. J. Immunol. 173: 4433-4442.
39. Bystry, R. S., V. Aluvihare, K. A. Welch, M. Kallikourdis, and A. G. Betz. 2001. B cells and professional APCs recruit regulatory T cells via CCL4. Nat. Immunol. 2: 1126-1132.
40. 3: involvement of NF-κB downregulation in transcriptional repression of the p40 gene. J. Clin. Invest. 101: 252-262.
41. + dendritic cells. J. Immunol 174: 2061-2070.
42. Remoli, M. E., E. Giacomini, G. Lutfalla, E. Dondi, G. Orefici, A. Battistini, G. Uze, S. Pellegrini, and E. M. Coccia. 2002. Selective expression of type I IFN genes in human dendritic cells infected with Mycobacterium tuberculosis. J. Immunol. 169: 366-374.
43. Komine, M., T. Kakinuma, S. Kagami, Y. Hanakawa, K. Hashimoto, and K. Tamaki. 2005. Mechanism of thymus- and activation-regulated chemokine (TARC)/CCL17 production and its modulation by roxithromycin. J. Invest. Dermatol. 125: 491-498.
44. Nakayama, T., K. Hieshima, D. Nagakubo, E. Sato, M. Nakayama, K. Kawa, and O. Yoshie. 2004. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J. Virol. 78: 1665-1674.
45. Berin, M. C, M. B. Dwinell, L. Eckmann, and M. F. Kagnoff. 2001. Production of MDC/CCL22 by human intestinal epithelial cells. Am. J. Physiol. 280: G1217-G1226.
46. Ghadially, H., X. L. Ross, C. Kerst, J. Dong, A. B. Reske-Kunz, and R. Ross. 2005. Differential regulation of CCL22 gene expression in murine dendritic cells and B cells. J. Immunol. 174: 5620-5629.
47. Blanar, M. A., L. C. Burkly, and R. A. Flavell. 1989. NF-κB binds within a region required for B-cell-specific expression of major histocompatibility complex class II gene Eαd. Mol. Cell. Biol. 9: 844-846.
48. Hinz, M., P. Loser, S. Mathas, D. Krappmann, B. Dorken, and C. Scheidereit. 2001. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/ Reed-Sternberg cells. Blood 97: 2798-2807.
49. Zhao, J., G.-J. Freeman, G. S. Gray, L. M. Nadler, and L. H. Glimcher. 1996. A cell type-specific enhancer in the human B7.1 gene regulated by NF-κB. J. Exp. Med. 183: 777-789.
50. Li, J., Z. Liu, S. Jiang, R. Cortesini, S. Lederman, and N. Suciu-Foca. 1999. T suppressor lymphocytes inhibit NF-κB-mediated transcription of CD86 gene in APC. J. Immunol. 163: 6386-6392.
51. Scheinman, R. I., P. C. Cogswell, A. K. Lofquist, and A. S. Baldwin, Jr. 1995. Role of transcriptional activation of IKα in mediation of immunosuppression by glucocorticoids. Science 270: 283-286.
52. Auphan, N., J. A. DiDonato, C. Rosette, A. Helmberg, and M. Karin. 1995. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270: 286-290.
53. 3 and glucocorticoid pathways. Biochem. Biophys. Res. Commun. 297: 645-652.
54. 3 analog. J. Steroid Biochem. Mol. Biol. 89-90: 443-448.
55. 3. Proc. Natl. Acad. Sci. USA 92: 10990-10994.
56. De Bosscher, K.. W. Vanden Berghe, L. Vermeulen, S. Plaisance, E. Boone, and G. Haegeman. 2000. Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl. Acad. Sci. USA 97: 3919-3924.
57. Hewison, M., L. Freeman, S. V. Hughes, K. N. Evans, R. Bland, A. G. Eliopoulos, M. D. Kilby, P. A. Moss, and R. Chakraverty. 2003. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. 170: 5382-5390.
58. 3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation 66: 828-831.
59. Ochando, J. C., C. Homma, Y. Yang, A. Hidalgo, A. Garin, F. Tacke, V. Angeli, Y. Li, P. Boros, Y. Ding, et al. 2006. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 7: 652-662.
60. + T cell anergy by peripheral blood DC2 precursors. Eur. J. Immunol 31: 2547-2557.
61. + dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 100: 383-390.
62. Wakkach, A., N. Fournier, V. Brun, J. P. Breittmayer, F. Cottrez, and H. Groux. 2003. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18: 605-617.
63. + DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 108: 481-492.
64. de Heer, H. J., H. Hammad, T. Soullie, D. Hijdra, N. Vos, M. A. Willart, H. C. Hoogsteden, and B. N. Lambrecht. 2004. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J. Exp. Med. 200: 89-98.
65. Baldwin, T., S. Henri, J. Curtis, M. O'Keeffe, D. Vremec, K. Shortman, and E. Handman. 1004. Dendritic cell populations in Leishmania major-infected skin and draining lymph nodes. Infect. Immun. 72: 1991-2001.